Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

ADVANCE is a randomized, double-blind, placebo-controlled, and multi-center study designed for examining the efficacy and safety of adjunctive use of pimavanserin in treating the above patient group.

Pimavanserin is already approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis under the trade name Nuplazid. Nuplazid was commercially launched in May this year.

According to the company’s press reelase, 40–50% of patients suffering from schizophrenia have prominent negative symptoms. Currently no drug is approved by the FDA for the treatment of these symptoms. Pimavanserin is selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors.

Meanwhile, the company is forging ahead with its multi-year plans of developing pimavanserin in indications beyond Parkinson’s disease psychosis. The company has completed enrollment in a phase II exploratory study on pimavanserin for the treatment of Alzheimer’s disease. Top-line results from this study are expected to be announced by the end of 2016.

Arbutus’ loss estimates narrowed from $2.15 to $1.77 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.

Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 301.64%.

Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters, with an average beat of 33.14%.

The Best Place to Start Your Stock Search

Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>

Resources

Client Support

Follow Us

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Zacks Investment Research is an A+ Rated BBB Accredited Business.

Copyright 2016 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1988-2015 and were examined and attested by Baker Tilly Virchow Krause, LLP, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.